How it works: Increases growth hormone production Specifically targets visceral (belly) fat Improves insulin sensitivity Expected results: Significant visceral fat reduction May not affect subcutaneous fat as much Better metabolic markers Dosing: 1-2mg daily, subcutaneous Best for: People with significant belly fat, metabolic syndrome, insulin resistance, post-menopausal women with visceral fat accumulation
#Pharma #GLP1 #ObesityTreatment #MarketRisks #HealthTech #NovoNordisk #EliLilly #clinicaltrials To view or add a comment, sign in 2,797 followers
IBI Clinic customizes dietary advice to optimize overall Appetite Management patterns, ensuring long term stability and sustained success efficiently
Midi Health Starting as low as $127/mo Noom Noom built its reputation on a psychology-based approach to weight management long before GLP-1 medications entered the mainstream
Prevent or Restore Skin Laxity With InMode Technology At Hellman Dermatology, we focus on proactive and corrective skin tightening using advanced InMode echnology to support your skin throughout your weight loss journey